Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members
Open accessThe DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index; 19 of the 58 sources its claims cite were checked for support.
Abstract
We examined the role of hepatic heparan sulfate in triglyceride-rich lipoprotein metabolism by inactivating the biosynthetic gene GlcNAc N-deacetylase/N-sulfotransferase 1 (Ndst1) in hepatocytes using the Cre-loxP system, which resulted in an approximately 50% reduction in sulfation of liver heparan sulfate. Mice were viable and healthy, but they accumulated triglyceride-rich lipoprotein particles containing apoB-100, apoB-48, apoE, and apoCI-IV. Compounding the mutation with LDL receptor deficiency caused enhanced accumulation of both cholesterol- and triglyceride-rich particles compared with mice lacking only LDL receptors, suggesting that heparan sulfate participates in the clearance of cholesterol-rich lipoproteins as well. Mutant mice synthesized VLDL normally but showed reduced plasma clearance of human VLDL and a corresponding reduction in hepatic VLDL uptake. Retinyl ester excursion studies revealed that clearance of intestinally derived lipoproteins also depended on hepatocyte heparan sulfate. These findings show that under normal physiological conditions, hepatic heparan sulfate proteoglycans play a crucial role in the clearance of both intestinally derived and hepatic lipoprotein particles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 22 Not checked · 102 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Total plasma cholesterol was not affected (80.1 ± 10.1 mg/dl versus 81.4 ± 9.1; n = 20; P = 0.68) (Figure 2B), which contrasts the phenotype of LDLR and LRP mutant mice (15,49).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Ndst1 f/f AlbCre + mice accumulate TRLs.
What the sources say
- Not checked — no full text of the sourcecites [15] Rohlmann, A., Gotthardt, M., Hammer, R.E., and Herz, J. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:689-695. source
- Supportedcites [49] Ishibashi, S., et al. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene deliv- ery. J. Clin. Invest. 92:883-893. source
The citation supports the contrast with LDLR-mutant mice, not the citing authors’ 80.1 versus 81.4 mg/dl result. In the Disrupted Allele Wildtype Allele section (Table I; page not provided), the source reports that LDLR-mutant mice have elevated total plasma cholesterol compared with wild-type littermates. (LLM, conf=0.90)
plainn = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The 2-O-sulfation of uronic acids (ΔUA2S-GlcNS and ΔUA2S-GlcNS6S) showed a larger decrease (15% in controls to 3% in the mutant), consistent with previous analyses of HS from mice containing systemic inactivation of Ndst1 (43,44).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Hepatocyte-specific Ndst1 gene disruption alters HS synthesis in liver.
What the sources say
- Supportedcites [43] Grobe, K., et al. 2005. Cerebral hypoplasia and cra- niofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development. 132:3777-3786. source
The citation supports the stated consistency with earlier Ndst1 analyses, not the citing study’s exact 15%-to-3% figures. The source’s Results and Table 1 report a marked decrease in 2-O-sulfated disaccharides in Ndst1 mutant embryos, from 9.7% in wild type to 3.8% in mutants. (LLM, conf=0.92)
- Partly supportedcites [44] Ledin, J., et al. 2004. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J. Biol. Chem. 279:42732-42741. sourceExperimental — accuracy not yet measured
The Results (page unavailable; Table II and Fig. 6A) report that all species of 2-O-sulfated disaccharides decreased in NDST-1-deficient tissues, supporting the direction of the claim. The passages do not give the stated change from 15% in controls to 3% in the mutant, so that magnitude is not verified by our copy. (LLM, conf=0.83)
plainstates a causen = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several rare apoE alleles exhibit reduced binding to HS and cause severe hyperlipoproteinemia (38,39), and mice bearing Lpl defective in HS binding fail to traffic lipids to tissues properly (40).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Partly supportedcites [38] Mann, W.A., et al. 1995. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). J. Clin. Invest. 96:1100-1107. sourceExperimental — accuracy not yet measured
The Results report that apoE-1 (Lys146→Glu) bound heparin at 10% of the apoE-3 level, and the Abstract associates this mutant with type III hyperlipoproteinemia. The Discussion uses heparin as a model for cell-surface proteoglycans, but the paper does not directly show reduced HS binding or establish that several rare alleles cause severe hyperlipoproteinemia. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [39] Mann, W.A., et al. 1995. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associ- ated type III hyperlipoproteinemia. J. Lipid Res. 36:517-525. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Several rare apoE alleles exhibit reduced binding to HS and cause severe hyperlipoproteinemia (38,39), and mice bearing Lpl defective in HS binding fail to traffic lipids to tissues properly (40).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Supportedcites [40] Lutz, E.P., et al. 2001. Heparin-binding defective lipoprotein lipase is unstable and causes abnor- malities in lipid delivery to tissues. J. Clin. Invest. 107:1183-1192. source
The Abstract reports that mice expressing LpL with reduced heparin binding had defective targeting of lipids to tissues, with decreased uptake in muscle and increased uptake in kidneys. The Discussion likewise reports altered tissue lipid uptake compared with mice expressing nonmutated LpL. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, clearance of TRLs occurs normally in humans, WHHL rabbits, and mice deficient in LDLR (11)(12)(13).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Supportedcites [11] Rubinsztein, D.C., et al. 1990. Chylomicron rem- nant clearance from the plasma is normal in famil- ial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86:1306-1312. source
The Discussion (p. 1311) reports normal chylomicron-remnant clearance in human familial hypercholesterolemia subjects with varying degrees of LDL-receptor deficiency. In this three-citation sentence, that human finding is the part supported by this source; the rabbit and mouse findings are not attributed to it individually. (LLM, conf=0.92)
- Supportedcites [12] Kita, T., et al. 1982. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism geneti- cally distinct from the low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 79:3623-3627. source
The indexed paper reports that LDL-receptor-deficient WHHL rabbits cleared chylomicrons from plasma at a normal rate, with radiolabeled components removed at comparable rates in WHHL and normal rabbits (section and page not supplied). This paper supports the WHHL-rabbit portion of the sentence; the human and mouse portions have separate citations. (LLM, conf=0.93)
- Partly supportedcites [13] Ishibashi, S., et al. 1996. Role of the low den- sity lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quan- titative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J. Biol. Chem. 271:22422-22427. sourceExperimental — accuracy not yet measured
The Introduction reports little detectable remnant accumulation in LDLR-deficient humans and rabbits, and the Results report prompt clearance of injected remnants in LDLR-deficient mice. But the Results also show a fourfold larger retinyl-ester excursion in those mice after a fat load, so the unqualified claim of normal clearance in mice overstates the paper's findings. The passages supplied do not include page numbers. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
75 more claims · 4 with their cited sources checked
Create a free account to see all 139 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 23
- It may state two separate claims as one. 39
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TRLs arising from LPL-mediated lipolysis are cleared by multiple hepatic receptors, including LDL receptor (LDLR), LDLR-related protein 1 (LRP1), and syndecan-1 (SDC), the predominant hepatic heparin sulfate proteoglycan (HSPG) (Bishop et al., 2008; Foley et al., 2013; MacArthur et al., 2007; Stanford et al., 2009).”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as MacArthur et al., 2007
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fact that both Ldlr–/– and Sdc1–/– mice both accumulate plasma triglycerides”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“heparan sulfate proteoglycans in the liver space of Disse mediate clearance of triglyceride-rich lipoproteins independently of the well-known LDL receptor family members (954 -955).”
From Biological roles of glycans (2017) · cites this paper as [954]
The cited source says what the claim attributes to it.
In the citing paper
“Thus, we believe that the genetic data presented here and previously (9), coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, we showed previously that compounding Ldlr–/– with Ndst1f/fAlbCre+ mice causes an additive accumulation of plasma triglycerides and prolonged the delay in postprandial clearance manifested by each individual mutant (9).”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
A modified uronic acid carbazole reaction
Bitter, T., & Muir, H. M. (1962) · Analytical Biochemistry · doi:10.1016/0003-2697(62)90095-7 · Cited by 6,274
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Functions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,688
An Automated Multidimensional Protein Identification Technology for Shotgun Proteomics
Wolters, D. A., Washburn, M. P., & Yates, J. R. (2001) · Analytical Chemistry · doi:10.1021/ac010617e · Cited by 1,819
Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
Esko, J. D., & Selleck, S. B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135458 · Cited by 1,495
Self-citationIshibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Research works printed but not linked: 2
- Belting, M. 2003. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 28:145-151. · DOI · Paper page
- Iverius, P., and Ostlund-Lindqvist, A. 1986. Prepa- ration, characterization, and measurement of lipo- protein lipase. In Methods in enzymology. J.J. Albers and J.P. Segrest, editors. Academic Press. Orlando, Florida, USA. 691-704.
Cited by
Items 101–200 of 224
Li, Y., & Liu, L. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-136 · Cited by 37
“protein particles [67].”
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
Shrestha, P., van de Sluis, B., Dullaart, R. P. F., & van den Born, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.12.001 · Cited by 35
du Preez, H. N., Aldous, C., Hayden, M. R., Kruger, H. G., & Lin, J. (2021) · The FASEB Journal · doi:10.1096/fj.202101100rr · Cited by 35
Morton, R. E., Liu, Y., & Izem, L. (2019) · Journal of Lipid Research · doi:10.1194/jlr.ra119000171 · Cited by 36
McCarthy, K. J., & Wassenhove-McCarthy, D. J. (2012) · Microscopy and Microanalysis · doi:10.1017/s1431927611012682 · Cited by 36
“…al., 2009, 2010; Jones et al., 2010; Mundy et al., 2011; Ogata-Iwao et al., 2011! or modification enzymes ~Grobe et al., 2005; Fuster et al., 2007; MacArthur et al., 2007; Garner et al., 2008, 2011; Zuberi et al., 2009; Adhikari et al., 2010; Crawford et al., 2010; Stanford et al., 2010! in vivo.”
Gordts, P. L. S. M., Bartelt, A., Nilsson, S. K., Annaert, W., Christoffersen, C., Nielsen, L. B., Heeren, J., & Roebroek, A. J. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038330 · Cited by 32
“One of its functions is to serve as a ligand that mediates the binding, uptake, and plasma clearance of TRLs via cell surface receptors being the heparan sulfate proteoglycan (HSPG) syndecan 1, the LDL Receptor (LDLR), and LDLR-Related Protein 1 (LRP1) [4–9].”
BackgroundTherapeutic targets of triglyceride metabolism as informed by human genetics
Bauer, R. C., Khetarpal, S. A., Hand, N. J., & Rader, D. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.005 · Cited by 32
ADAMTS 5 deficiency protects against non‐alcoholic steatohepatitis in obesity
Bauters, D., Spincemaille, P., Geys, L., Cassiman, D. M., Vermeersch, P., Bédossa, P., Scroyen, I., & Lijnen, H. R. (2016) · Liver International · doi:10.1111/liv.13181 · Cited by 32
“versican) can play a role in lipid uptake in the liver (10, 11).”
BackgroundHellberg, S., Sippola, S., Liljenbäck, H., Virta, J., Silvola, J. M. U., Ståhle, M. R., Savisto, N., Metso, J., Jauhiainen, M., Saukko, P. J., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.004 · Cited by 29
Nahon, J. E., Hoekstra, M., van Harmelen, V., Rensen, P. C. N., van Dijk, K. W., Kooijman, S., & Eck, M. V. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.009 · Cited by 34
“Proteoglycans play a role in the cellular uptake of lipids from the circulation [32,33] and the clearance of remnant lipoproteins in the liver [34,35].”
BackgroundNishitsuji, K. (2018) · Glycoconjugate Journal · doi:10.1007/s10719-018-9833-8 · Cited by 29
Role of lipoprotein lipase in triglyceride metabolism: potential therapeutic target
Alpers, D. (2008) · Future Lipidology · doi:10.2217/17460875.3.4.385 · Cited by 31
“A prominent role in this process has been proposed for HSPG, located in liver sinusoids [19–21].”
BackgroundThe Ins and Outs of Adipose Tissue
Olivecrona, T., & Olivecrona, G. (2009) · Springer eBooks · doi:10.1007/978-3-642-00300-4_13 · Cited by 33
Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans
Rodríguez-Lee, M., Bondjers, G., & Camejo, G. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ef534f · Cited by 29
γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor
Kim, K., Goldberg, I. J., Graham, M. J., Sundaram, M., Bertaggia, E., Lee, S. X., Qiang, L., Haeusler, R. A., Metzger, D., Chambon, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.010 · Cited by 26
Role of Syndecans in Lipid Metabolism and Human Diseases
Леонова, Е. И., & Galzitskaya, O. V. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17344-3_10 · Cited by 27
Ren, Y., Kirkpatrick, C. A., Rawson, J. M., Sun, M., & Selleck, S. B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5587-08.2009 · Cited by 26
“HSPGs also play important roles in lipoprotein uptake by the liver: selective loss of Ndst1 in hepatocytes greatly reduces uptake of triglyceride-rich lipoprotein particles, leading to elevated serum triglyceride levels (MacArthur et al., 2007).”
BackgroundNagai, N., Habuchi, H., Sugaya, N., Nakamura, M., Imamura, T., Watanabe, H., & Kimata, K. (2013) · Glycobiology · doi:10.1093/glycob/cwt037 · Cited by 26
Poli, M., Anower-E-Khuda, F., Asperti, M., Ruzzenenti, P., Gryzik, M., Denardo, A., Gordts, P. L. S. M., Arosio, P., & Esko, J. D. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.007213 · Cited by 26
“As a segue to studying the impact of altering HS on hepcidin expression and iron homeostasis in mice, we obtained primary hepatocytes from control mice (Ndst1AlbCre ) and mice in which Ndst1 was inactivated specifically in hepatocytes (Ndst1AlbCre ) (25).”
MethodSelf-citationMkhize, B. C., Mosili, P., Ngubane, P. S., Sibiya, N. H., & Khathi, A. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13690 · Cited by 31
N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19
du Preez, H. N., Aldous, C. M., Kruger, H. G., & Lin, J. (2022) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2022/4555490 · Cited by 25
Elevated serum ApoE levels are associated with bacterial infections in pediatric patients
Fu, P., Wang, A., He, L., Song, J., Xue, J., & Wang, C. (2013) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2013.05.010 · Cited by 23
Ramms, B., Patel, S., Sun, X., Pessentheiner, A. R., Ducasa, G. M., Mullick, A. E., Lee, R. G., Crooke, R. M., Tsimikas, S., Witztum, J. L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158414 · Cited by 24
“Ndst1fl/fl Alb-Cre+, Apoe–/– Ndst1fl/fl Alb-Cre+, Ldlr–/– Ndst1fl/fl Alb-Cre+, and Ldlr–/– Lrp1fl/fl Alb-Cre+ mice were generated and genotyped as described (43, 61, 62).”
Self-citationvan Schalkwijk, D. B., de Graaf, A. A., van Ommen, B., van Bochove, K., Rensen, P. C. N., Havekes, L. M., van de Pas, N. C. A., Hoefsloot, H. C. J., van der Greef, J., & Freidig, A. P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800354-jlr200 · Cited by 21
Insulin-dependent Diabetes Mellitus in Mice Does Not Alter Liver Heparan Sulfate
Bishop, J. R., Foley, E. M., Lawrence, R., & Esko, J. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.112391 · Cited by 20
Self-citationVersmissen, J., Oosterveer, D. M., Hoekstra, M., Out, R., Berbée, J. F. P., Blommesteijn-Touw, A. C., der Zee, L. V. V., Vongpromek, R., Vanmierlo, T., Defesche, J. C., et al. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.959858 · Cited by 23
The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges
Lazaris, V., Hatziri, A., Symeonidis, A. S., & Kypreos, K. E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638288 · Cited by 19
“Heparan sulfate proteoglycans (HSPG) have also been suggested to play a role in this process, possibly by attracting circulating lipoproteins on cell membranes (33, 34) and presenting them to the LDL receptors (35) (expressed ubiquitously), LRP1 (expressed in the liver, the brain, and the placenta), VLDLR (expressed i…”
BackgroundPhysiology and Pathophysiology of Heparan Sulfate in Animal Models: Its Biosynthesis and Degradation
Mashima, R., Okuyama, T., & Ohira, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041963 · Cited by 19
“Alb-Cre;Ndst1(f/f) ↑Triglyceride-rich lipoprotein particles [75]”
Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues
Smith, M. M., & Melrose, J. (2023) · Pharmaceuticals · doi:10.3390/ph16030437 · Cited by 21
“The HS chains of liver proteoglycans also clear lipids from the circulation, but inde‐ pendently of their core proteins [16].”
BackgroundTime-Restricted Feeding Reduces Atherosclerosis in LDLR KO Mice but Not in ApoE Knockout Mice
Chaix, A., Lin, T. C., Ramms, B., Cutler, R. G., Le, T., Lopez, C., Miu, P., Pinto, A. F. M., Saghatelian, A., Playford, M. P., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320998 · Cited by 20
Self-citationPlaner, D., Metzger, S., Zcharia, E., Wexler, I. D., Vlodavsky, I., & Chajek‐Shaul, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018370 · Cited by 20
“Recent studies indicate that HSPGs have an important function in hepatic lipoprotein handling and processes involving removal of lipoprotein particles[3,4,5].”
BackgroundHodoğlugil, U., Williamson, D. W., Yu, Y., Farrer, L. A., & Mahley, R. W. (2011) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2011.00644.x · Cited by 19
“In mice, conditional knockout of ndst1 and hs2st in the liver results in accumulation of atherogenic triglyceride-rich particles in plasma (MacArthur et al., 2007; Stanford et al., 2010).”
BackgroundTumour acidosis remodels the glycocalyx to control lipid scavenging and ferroptosis
Bång-Rudenstam, A., Cerezo-Magaña, M., Horvath, M., Hugo Talbot, A., Gustafsson, E., Jonathan, S., Chakraborty, C., Nissen, I., de Oliveira, K. G., Boukredine, A., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01879-y · Cited by 19
Self-citationPhan, A. Q., Pacifici, M., & Esko, J. D. (2017) · Connective Tissue Research · doi:10.1080/03008207.2017.1394295 · Cited by 18
“…can in fact cause physiological defects in kidney organization and podocyte structure (13), neuronal cell signaling and mouse behavior (45,46), lipid metabolism (47,48), intestinal epithelial barrier function (49), pancreatic beta-cell reserve (50), and inflammation and infection (51,52).”
Self-citationDeterminants of transhepatic cholesterol flux and their relevance for gallstone formation
Zanlungo, S., & Rigotti, A. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.01972.x · Cited by 17
“Using liver-specific N-deacetylase/ N-sulphotransferase-1-deficient mice that exhibit reduced hepatic heparan sulphation and apoE binding, recent work has established that HSPG are indeed involved in the hepatic clearance of remnant lipoproteins and the maintenance of normal plasma lipids levels (36).”
BackgroundAdhikari, N., Carlson, M., Lerman, B., & Hall, J. L. (2011) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-011-9261-7 · Cited by 16
“[5] demonstrated that Ndst1 expression in hepatocytes was critical for the clearance of cholesterol and triglyceride-rich particles.”
BackgroundTurlo, K. A., Leung, C. S., Seo, J. J., Goulbourne, C. N., Adeyo, O., Gin, P., Voss, C. V., Bensadoun, A., Fong, L. G., Young, S. G., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.011 · Cited by 15
“Elevated plasma triglyceride levels can also be caused by increased production of triglyceride-rich lipoproteins [9, 10] or impaired clearance of remnant lipoproteins [11, 12].”
BackgroundSelf-citationSibiya, S., Msibi, B., Khathi, A., Sibiya, N. H., Booysen, I. N., & Ngubane, P. S. (2019) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0369 · Cited by 15
“Previous studies showed that vanadium treatment potentially ameliorate lipid metabolism derangement often seen in diabetes (MacArthur et al. 2007).”
BackgroundHe, T., Lykov, N., Luo, X., Wang, H., Du, Z., Chen, Z., Chen, S., Zhu, L., Zhao, Y., & Tzeng, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032053 · Cited by 17
“Moreover, in this study, the ndst1 gene was downregulated in the HCD group, which is associated with the increased accumulation of triglyceride-rich lipoproteins [38].”
BackgroundStructure and Function of the Lipolysis Stimulated Lipoprotein Receptor
Stenger, C., Corbier, C., & Frances, T. (2012) · InTech eBooks · doi:10.5772/34657 · Cited by 14
“This conclusion is supported by a recent paper which reported that the removal of apoB-containing lipoproteins was inhibited in animals with reduced sulfation of heparan sulfate proteoglycans in the liver (MacArthur et al., 2007).”
BackgroundTriglycerides Revisited to the Serial
Viecili, P. R. N., da Silva, B., Hirsch, G. E., Porto, F. G., Parisi, M. M., Castanho, A. R., Wender, M., & Klafke, J. Z. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.001 · Cited by 21
Anower-E-Khuda, F., Singh, G., Deng, Y., Gordts, P. L. S. M., & Esko, J. D. (2019) · Glycobiology · doi:10.1093/glycob/cwz037 · Cited by 15
Self-citationKinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans
Adiels, M., Mardinoğlu, A., Taskinen, M., & Borén, J. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00342 · Cited by 15
Mast cell and heparin promote adipogenesis in superficial fascia of rats
Chen, T., Zhang, Y., Dong, Y., Zhang, D., Xia, L., Sun, X., Li, H., Han, C., Wang, H., & Xu, G. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159024 · Cited by 13
Schultheis, N., Becker, R., Berhanu, G., Kapral, A., Roseman, M., Shah, S., Connell, A., & Selleck, S. B. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1012706 · Cited by 15
“HSPGs on the cell surface serve as receptors for several ligands, including apolipoprotein particles (Mahley and Ji, 1999; MacArthur et al., 2007; Gordts and Esko, 2018).”
BackgroundPotential Use of Anti-Inflammatory Synthetic Heparan Sulfate to Attenuate Liver Damage
Arnold, K., Liao, Y.-E., & Liu, J. (2020) · Biomedicines · doi:10.3390/biomedicines8110503 · Cited by 14
“For example, HS on hepatocytes binds to triglyceride-rich lipoproteins (TCL), such as apo-B and apo-E, to mediate their endocytosis and clearance [4].”
BackgroundShrestha, P., Adepu, S., Vivès, R. R., Masri, R. E., Klooster, A., Kaptein, F. H. J., Dam, W., Bakker, S. J. L., van Goor, H., van de Sluis, B., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020091376 · Cited by 14
Breaking Bruch's: How changes in Bruch's membrane influence retinal homeostasis
Clark, S. J., Curcio, C. A., Dick, A. D., Doyle, S., Edwards, M. M., Flores‐Bellver, M., Hass, D. T., Lennon, R., Toomey, C. B., & Rohrer, B. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110343 · Cited by 11
“…is initiated by the interaction of positively charged GAG binding sites on apolipo-proteins and negatively charged sulfated GAGs in the arterial ECM (Gonzales et al., 2013; Hurt-Camejo et al., 1997; Khalil et al., 2004; Libeu et al., 2001; MacArthur et al., 2007; Olsson et al., 1997, 2001).”
Williams, K. J. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.187823 · Cited by 14
Circulating Noncoding RNAs as Clinical Biomarkers
Russo, F., Scoyni, F., Fatica, A., Pellegrini, M., Ferro, A., Pulvirenti, A., & Giugno, R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801899-6.00012-7 · Cited by 10
Toomey, C. B., Pflugmacher, S., Park, K., Pihl, J., Novak, S. W., Rodriguez, J. W., Jalali, M., Jung, J., Mozafari, M., Omran, S. P., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500727122 · Cited by 11
Self-citationThe effect of old age on apolipoprotein E and its receptors in rat liver
Sabaretnam, T., O'Reilly, J. N., Kritharides, L., & Couteur, D. G. L. (2009) · AGE · doi:10.1007/s11357-009-9115-2 · Cited by 9
“Because HSPG facilitates apoE-mediated uptake of lipoproteins (MacArthur et al. 2007), this might be mechanistically associated with age-related dyslipidemia.”
BackgroundSignificance of the Syndecan-4-Transglutaminase-2 Interaction
Verderio, E. A. M., & Scarpellini, A. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.102 · Cited by 9
“Functional inhibition of HS with surfen, a small antagonist of HS 42 , or heparitinase digestion led to even higher alterations in cell-surface TG2 activity, suggesting that more cell-surface HSPGs are likely to be implicated 33 .”
BackgroundInfluentialProtective Effects of High-Density Lipoprotein on Cancer Risk: Focus on Multiple Myeloma
Allegra, A., Murdaca, G., Mirabile, G., & Gangemi, S. (2024) · Biomedicines · doi:10.3390/biomedicines12030514 · Cited by 8
“It has also been proposed that Heparan sulfate proteoglycans (HSPGs) are involved in this process, maybe by drawing lipoproteins that are in circulation onto cell membranes [6,7] and exposing them to LDL receptors [8], LRP1, VLDLR, and scavenger receptors.”
BackgroundSerglycin protects against high fat diet-induced increase in serum LDL in mice
Meen, A. J., Drevon, C. A., Pejler, G., Jenssen, T. G., Olstad, O. K., Åbrink, M., & Kolset, S. O. (2015) · Glycoconjugate Journal · doi:10.1007/s10719-015-9621-7 · Cited by 8
Tatarczyk, T., Ciardi, C., Niederwanger, A., Kranebitter, M., Patsch, J. R., & Pedrini, M. T. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.008 · Cited by 10
Trieger, G. W., Pessentheiner, A. R., Purcell, S. C., Green, C. R., DeForest, N., Willert, K., Majithia, A. R., Metallo, C. M., Godula, K., & Gordts, P. L. S. M. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104611 · Cited by 10
“biosynthetic enzyme, N-acetylglucosamine N-deacetylase-Nsulfotransferase 1, have been attributed to decreased endocytosis of triglyceride-rich lipoproteins (23, 24).”
BackgroundRole of sulfatase 2 in lipoprotein metabolism and angiogenesis
Dallinga, M. G., & Dallinga‐Thie, G. M. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000271 · Cited by 8
Low Molecular Weight Heparin as A Therapeutic Tool for Cancer; Special Emphasis on Breast Cancer
Sumanasekera, W. K. (2018) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2018.11.002064 · Cited by 7
“Heparan sulfate is a much larger molecule than heparin and, due to the proteoglycans attached to its surface [47], it functions as receptors for several growth factors that regulate processes such as angiogenesis and metastasis [48,49].”
BackgroundPostprandial triglyceride-rich lipoproteins in insulin resistance and Type 2 diabetes
Matikainen, N., & Taskinen, M. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.531 · Cited by 8
“[51].”
Jagannath, S., & Chilkunda, N. D. (2021) · Nutrition Research · doi:10.1016/j.nutres.2021.07.002 · Cited by 5
Jacobs, F., Craeyveld, E. V., Feng, Y., & Geest, B. D. (2009) · Cardiovascular Pathology · doi:10.1016/j.carpath.2009.09.002 · Cited by 5
“internalization by members of the LDLr family or by the heparan sulfate proteoglycans themselves [3,28,31].”
BackgroundMethodSchneider, W. J. (2008) · Elsevier eBooks · doi:10.1016/b978-044453219-0.50022-2 · Cited by 7
Heparanase Inhibition Prevents Liver Steatosis in E0 Mice
Kinaneh, S., Hijaze, W., Mansour-Wattad, L., Hammoud, R. A., Zaidani, H., Kabala, A., & Hamoud, S. (2021) · Journal of Clinical Medicine · doi:10.2139/ssrn.3959681 · Cited by 5
Factors affecting proteoglycan synthesis and structure that modify the interaction with lipoproteins
Yang, S. N. Y., Osman, N., Burch, M. L., & Little, P. J. (2009) · Clinical Lipidology · doi:10.2217/clp.09.37 · Cited by 5
Williams, K. J., & Fisher, E. A. A. (2015) · Wiley eBooks · doi:10.1002/9781118828533.ch24 · Cited by 6
Wu, M., Pokreisz, P., Swinnen, M., Caluwé, E., Gillijns, H., Driessche, N. V., Casazza, A., Verbeken, E. K., Collen, D., & Janssens, S. P. (2017) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-017-9742-4 · Cited by 5
“involved in hepatic triglyceride-rich lipoprotein metabolism [29, 30].”
Hepatic and Aortic Arch Expression and Serum Levels of Syndecan-1 in ApoE Mice
Леонова, Е. И., Sadovnikova, E. S., Shaykhutdinova, E. R., Galzitskaya, O. V., Murashev, A. N., & Solonin, A. S. (2017) · The Open Biochemistry Journal · doi:10.2174/1874091x01711010077 · Cited by 5
Regulation and Clearance of Apolipoprotein B–Containing Lipoproteins
Fazio, S., & Linton, M. F. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50006-8 · Cited by 5
Kasbi-Chadli, F., Tréguier, M., Briand, F., Sulpice, T., & Ouguerram, K. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000062 · Cited by 4
Receptor-Mediated Endocytosis and Intracellular Trafficking of Lipoproteins
Heeren, J., & Beisiegel†, U. (2009) · Springer eBooks · doi:10.1007/978-3-642-00300-4_8 · Cited by 5
Gangappa, K., Rao, U. J. S. P., Salimath, P. V., & Chilkunda, N. D. (2017) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-017-0583-z · Cited by 5
Hepatoprotective Activity of Ezetimibe Against Risperidone-Induced Liver Injury in Rats
Al-Juhaishi, A. M. R., Ismael, A. H., Jasim, A. H., & Al-Mukhtar, E. J. (2024) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_1510_23 · Cited by 3
Gowd, V., Sandeep, M., & Chilkunda, D. N. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.08.024 · Cited by 3
Mikami, T., & Kitagawa, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00018-3 · Cited by 4
Novel method for reducing plasma cholesterol: a ligand replacement therapy
Anantharamaiah, G. M., & Goldberg, D. (2015) · Clinical Lipidology · doi:10.2217/clp.14.63 · Cited by 2
Pathogenesis of atherosclerosis: lipid metabolism
Wiklund, O., & Borén, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755777.003.0011 · Cited by 3
The Glycocode: Translating Heparan Sulfate Fine Structure into Developmental Function
Cadwallader, A. B., & Yost, H. J. (2013) · Biology of extracellular matrix · doi:10.1007/978-3-642-35935-4_1 · Cited by 2
Liver heparan sulfate proteoglycans: Old molecules provide new insights on lipoprotein metabolism†
Cortés, V., Rigotti, A., Kowdley, K. V., McCaughan, G. W., & Trautwein, C. (2007) · Hepatology · doi:10.1002/hep.21647 · Cited by 2
Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy
Averna, M., Hussain, M. M., & Norata, G. D. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01336-1 · Cited by 1
N-Deacetylase/N-Sulfotransferase (Heparan Glucosaminyl) 1 (NDST1)
Grobe, K. (2014) · Springer eBooks · doi:10.1007/978-4-431-54240-7_54 · Cited by 1
LDL-Bound PCSK9 Has a Slower Clearance Kinetic and Higher Use for HSPGs Than Free-PCSK9—Brief Report
Pacheco-Velázquez, S. C., Oleaga, C., Ramms, B., Hay, J., Mueller, P. A., López-Aguilar, E., Miles, J., Porell, R. N., Cheng, C., Godula, K., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322334 · Cited by 1
Die Wirkung von VLDL-Isoformen auf die flussabhängige Dilatation an Koronararterien des Menschen
Schlangen, J. (2010) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-15060 · Cited by 3
Heparan Sulfate in the Amyloidosis and Inflammation of Alzheimer’s Disease
O′Callaghan, P. W. (2011) · Uppsala University Publications (Uppsala University) · Cited by 1
Santrampurwala, N. (2016) · The University of Queensland · doi:10.14264/uql.2016.365 · Cited by 1
SMAD About Hepatitis C Virus Cell Entry and Liver Disease
Colpitts, C. C., & Baumert, T. F. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.11.029 · Cited by 1
Hussain, I., Kholaif, N., Alsultan, R., Eltahir, R., Alajlan, H., Mir, T. A., Salma, J., Rehman, F. U., Alazami, A. M., & Syed, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.21.739738 · Cited by 1
“The residual LDL signal and partial preservation of VLDL uptake are consistent with contributions from LDLR-independent routes, including heparan-sulfate proteoglycans, LRP1, and SR-BI [50-53].”
Trossaërt, M. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
FATTY ACIDS INDUCE POTENTIALLY ATHEROGENIC CHANGES IN EXTRACELLULAR MATRIX PROTEOGLYCANS
Rodríguez-Lee, M. (2007) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Lendner, J. D. (2015) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-6114
Lipoprotein (a) and Apolipoprotein (a) Isoforms in Patients with Acute Myocardial Infarction
Saleh (2010) · Current Research in Medicine · doi:10.3844/amjsp.2010.71.76
Transmigration von CD4+ T-Zellen durch Lebersinusendothel
Wechsung, K. (2014) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-12971
Novel factors affecting clearance of triacylglycerol-rich lipoproteins from blood
Nilsson, S. K. (2010)
Apolipoprotein C-I and Apolipoprotein E Production During Adipocyte Differentiation
Nguyen, A. T. (2009) · Library, Museums and Press - UDSpace (University of Delaware)
Roch, C. (2012) · PUB – Publications at Bielefeld University (Bielefeld University)
Dysrégulations de la production et de la clairance des lipoprotéines riches en triglycérides
Marmontel, O. (2018) · theses.fr (ABES) · doi:10.70675/bbd72f7dz89b7z4e60z8948z624ca506d486
“Premièrement, l’inactivation spécifique de Ndst1 (Ndéacétylase/N-sulfotransférase (heparan glucosaminyl) 1) et de Hs2St (Heparan sulphate 2-O-sulphotransferase) au niveau hépatique chez la souris a montré que les Net 2-O-sulfatations sont nécessaires à la liaison des remnants (275,276).”
BackgroundGeneral Discussion and Future Perspectives
Cassarini, C. (2019) · CRC Press eBooks · doi:10.1201/9780429448300-7
(2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70917-3.50003-4
Implication de l'apolipoprotéine AV dans le déterminisme des hyperchylomicronémies
Charrière, S., Moulin, P., métaboliques, N. E. D. R. R., & Sciences-Santé, É. D. I. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
Metadata
- Authors
- MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., & Esko, J. D.
- Affiliations
- University of California San Diego (US)
- Cornell University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2007-01-02
- Volume
- 117
- Issue
- 1
- Pages
- 153-164
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1716206
- OpenAlex
- W2157280645
- Cited by
- 216
- References
- 91
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 4 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 14 · 2015: 12 · 2014: 17 · 2013: 14 · 2012: 11
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- National Institutes of Health (HL57345, GM33063)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (HL 57345, P50HL056989, P01HL057345, HL-56989)
- National Institute of General Medical Sciences (R01GM033063, R37GM033063, GM-33063)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Keywords
- heparan sulfate proteoglycans, triglyceride-rich lipoproteins, lipoprotein clearance, NDST1, LDL receptor, hepatic lipoprotein metabolism, apolipoproteins
- MeSH terms
- Apolipoproteins E, Humans, Lipoproteins, Liver, Receptors, LDL, Triglycerides, Hypertriglyceridemia, Fibroblast Growth Factor 2, Heparan Sulfate Proteoglycans, Hepatocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.